Galderma Research & Development

Centre International De Recherches Dermatologiques Galderma

Societe L'oreal Sa

Andre Jomard

Laurence Clary

Michel Rivier

Pascal Collette

Claire Bouix-Peter

Michel Demarchez

Etienne Thoreau

Thibaud Biadatti

Johannes Voegel

Alvin Berger

Patricia Rossio

Novel biaromatic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.

Biaromatic compounds which activate PPAR&#x3b3; type receptors and cosmetic/pharmaceutical compositions comprised thereof

Novel biaromatic vitamin D analogues have the general formula (I): and are suited for a wide variety of pharmaceutical applications, whether in human or veterinary medicine, and also for cosmetic applications.

Vitamin D analogues

Novel polycyclic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.

Polycyclic compounds which modulate PPAR&#x3b3; type receptors and cosmetic/pharmaceutical compositions comprised thereof

Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof

The invention concerns fatty acids uninterrupted by a methylene group as anti-inflammatory agents in superficial tissues of mammals, more particularly a pharmaceutical or cosmetic topical composition comprising, as an active ingredient, at least one fatty acid uninterrupted by a methylene group corresponding to formula (I),

Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals

The present invention relates to the use of at least one ligand which is specific for RXR receptors, in the preparation of a pharmaceutical composition to be administered systemically and intended to increase the cellular proliferation and/or differentiation modulatory activity of a ligand for at least one receptor of the superfamily of steroidal/thyroidal receptors, other than a ligand which is specific for the RXR receptors, and which can heterodimerize with the RXRs, which is applied topically.

Use of ligands which are specific for RXR receptors

Use of inhibitors of retinoic acid activity for wound healing

The present invention relates to a process for identifying RAR-antagonist molecules, characterized in that it comprises the following steps: (i) a sufficient amount of an RAR-agonist molecule is applied topically to a part of the skin of a mammal, (ii) a molecule capable of having an RAR-antagonist activity is administered systemically or topically to this same mammal, or to this same part of the skin of the mammal, before, during or after step (i), and (iii) the response on that part of the skin of the mammal thus treated is evaluated.

Process for identifying RAR-receptor-antagonist compounds

The present invention relates to a process for identifying RXR-agonist molecules, characterized in that it comprises the following steps: (i) a sufficient amount of a compound which is an active ligand for at least one receptor of the super-family of steroidal/thyroidal receptors, other than an RXR-receptor-specific ligand, and which can heterodimerize with the RXRs, is applied topically to a part of the skin of a mammal, (ii) a molecule capable of having an RXR-agonist activity is administered systemically or topically to this same mammal, or to this same part of the skin of the mammal, before, during or after step (i), and (iii) the response on that part of the skin of the mammal thus treated is evaluated.

Growing community of inventors

Saint Vallier de Thiey, France

Andre Jomard